different kidney diseases being targeted so got to be cautious about comparing , but this asset (68% proteinurya reduction against placebo which is huge!) and the Novartis news yesterday that Fabhalta got fda accelerated approval for Iga nepropathy, 38% reduction proteinuria vs placebo just serves to highlight imo the relatively small effect of the dimx asset as a protein in urine reducer (17% vs placebo in phase 2).
Banter and general comments, page-25
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $228.3M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 44.0¢ | 40.5¢ | $867.2K | 2.085M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 59536 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 148530 | 6 |
View Market Depth
| Last trade - 13.53pm 16/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |